Paul B. Chapman

Weill Cornell Medical College
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Emerging evidence suggests that concurrent COVID-19 mRNA vaccination may enhance immune checkpoint inhibitors (ICIs) effectiveness by augmenting antitumor immune activation. Yet real-world estimates of survival benefit across cancers and clinical subgroups are limited. We emulated a randomized trial comparing two strategies at initiation of first-line ICI therapy: receipt of ≥1 COVID-19 mRNA vaccine within 100 days of ICI initiation versus no vaccination. Using the TriNetX linked network, we identified 7,966 adults with lung, melanoma, or kidney cancers who initiated first-line ICI between Sep 2020 and Nov 2024, among whom 458 received a COVID-19 vaccine within ±100 days of initiation. Vaccination was associated with improved overall survival (OS) and treatment-free survival (TFS) in lung cancer (OS aHR, 0.81; 95% CI, 0.74–0.89; P<0.001), with a modestly longer 3-year mean OS of 2.33 months (95% CI, 1.41–3.23; P<0.001). Vaccination was not associated with TFS or OS improvement in kidney or melanoma.

Year:

2025

Purpose: The Adaptively Dosed ImmunoTherapy Trial (ADAPT-IT;NCT03122522) investigated adaptive ipilimumab discontinuation in melanoma based on early radiographic assessment. Initial findings indicated similar effectiveness compared with conventional nivolumab-ipilimumab (nivo-ipi). Exploratory biomarker analyses and final clinical results are now reported. Patients and Methods: Patients with unresectable melanoma received two doses of nivo-ipi. Radiographic assessment at Week 6 informed continuation of ipilimumab before nivolumab maintenance. The primary endpoint was overall response rate at Week 12. Plasma was assayed for circulating tumor DNA and 10 cytokines using a multiplex immunoassay. Flow cytometry of peripheral blood mononuclear cells was performed with an 11-color panel. Results: Among the treated patients, expansion of proliferating T-cell populations was observed in responders and nonresponders. Baseline IL6 levels were low in patients achieving an objective radiographic response (median 1.30 vs. 2.86 pg/mL; P = 0.025). High baseline IL6 levels were associated with short progression-free survival [PFS; HR = 1.24, 95% confidence interval (CI), 1.01–1.52; P = 0.041]. At Week 6, patients with response had lower average tumor variant allele fractions than nonresponders (median 0.000 vs. 0.019; P = 0.014). Greater increases in average variant allele fractions from baseline to Week 6 correlated with short PFS (HR = 1.11, 95% CI, 1.01–1.21; P = 0.023). Week 12 overall response rate was 47% (95% CI, 35%–59%) with a median follow-up of 34 months among survivors. Median PFS was 21 months (95% CI, 10–not reached); 76% of responses (95% CI, 64%–91%) persisted at 36 months. Conclusions: Adaptively dosed nivo-ipi responses are durable and resemble historical data for conventional nivo-ipi. Baseline IL6 and circulating tumor DNA changes during treatment warrant further study as biomarkers of nivo-ipi response.

Year:

2024

Purpose: The Adaptively Dosed ImmunoTherapy Trial (ADAPT-IT;NCT03122522) investigated adaptive ipilimumab discontinuation in melanoma based on early radiographic assessment. Initial findings indicated similar effectiveness compared with conventional nivolumab-ipilimumab (nivo-ipi). Exploratory biomarker analyses and final clinical results are now reported. Patients and Methods: Patients with unresectable melanoma received two doses of nivo-ipi. Radiographic assessment at Week 6 informed continuation of ipilimumab before nivolumab maintenance. The primary endpoint was overall response rate at Week 12. Plasma was assayed for circulating tumor DNA and 10 cytokines using a multiplex immunoassay. Flow cytometry of peripheral blood mononuclear cells was performed with an 11-color panel. Results: Among the treated patients, expansion of proliferating T-cell populations was observed in responders and nonresponders. Baseline IL6 levels were low in patients achieving an objective radiographic response (median 1.30 vs. 2.86 pg/mL; P = 0.025). High baseline IL6 levels were associated with short progression-free survival [PFS; HR = 1.24, 95% confidence interval (CI), 1.01–1.52; P = 0.041]. At Week 6, patients with response had lower average tumor variant allele fractions than nonresponders (median 0.000 vs. 0.019; P = 0.014). Greater increases in average variant allele fractions from baseline to Week 6 correlated with short PFS (HR = 1.11, 95% CI, 1.01–1.21; P = 0.023). Week 12 overall response rate was 47% (95% CI, 35%–59%) with a median follow-up of 34 months among survivors. Median PFS was 21 months (95% CI, 10–not reached); 76% of responses (95% CI, 64%–91%) persisted at 36 months. Conclusions: Adaptively dosed nivo-ipi responses are durable and resemble historical data for conventional nivo-ipi. Baseline IL6 and circulating tumor DNA changes during treatment warrant further study as biomarkers of nivo-ipi response.

Year:

2024

Year:

2022

Collaborators (5)

Judy Zhong

Professor and Division Chief

Weill Cornell Medicine

UNITED STATES
View details

Allison Betof Warner

Assistant Professor, Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy

Stanford University

UNITED STATES
View details

Michael A. Postow

Weill Cornell Medical College

UNITED STATES
View details

Alexander Noor Shoushtari

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Jedd Wolchok

Director

Weill Cornell Medicine

UNITED STATES
View details